HALNEURON Emerging Drug Insight and Market Forecast – 2032

HALNEURON Emerging Drug Insight and Market Forecast – 2032

“HALNEURON Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about HALNEURON for Chemotherapy-induced Peripheral Neuropathy in the 7MM. A detailed picture of the HALNEURON for Chemotherapy-induced Peripheral Neuropathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the HALNEURON for Chemotherapy-induced Peripheral Neuropathy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the HALNEURON market forecast, analysis for Chemotherapy-induced Peripheral Neuropathy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Chemotherapy-induced Peripheral Neuropathy.

Drug Summary

HALNEURON (Tetrodotoxin or TTX) is a small molecule, targeting moderate-severe neuropathic pain without the side effects associated with opioid use. TTX blocks the voltage-gated sodium channels (VGSCs) found on nerves that conduct pain impulses, which are known to be affected in chronic pain conditions. HALNEURON is an injectable formulation of tetrodotoxin, a novel small molecule with action on the peripheral nervous system. HALNEURON does not cross the blood-brain-barrier and therefore is without the common side effects of euphoria, addiction, tolerance, sedation, and confusion experienced by opioids and other analgesics. TTX is highly specific to VGSCs on the periphery without effects on the central nervous system. HALNEURON is 3000 times more potent than morphine without the opioid-like side effects. It is non-addictive, with no tolerance issues, and has a long duration of pain relief.

WEX has completed 15 clinical trials with HALNEURON, with more than 700 subjects treated to date. WEX is in the process of launching its pivotal Phase III trial for HALNEURON to treat Chemotherapy-Induced Neuropathic Pain (CINP).



Scope of the Report

The report provides insights into:

A comprehensive product overview including the HALNEURON description, mechanism of action, dosage and administration, research and development activities in Chemotherapy-induced Peripheral Neuropathy.

Elaborated details on HALNEURON regulatory milestones and other development activities have been provided in this report.

The report also highlights the HALNEURON research and development activity in Chemotherapy-induced Peripheral Neuropathy details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around HALNEURON.

The report contains forecasted sales of HALNEURON for Chemotherapy-induced Peripheral Neuropathy till 2032.

Comprehensive coverage of the late-stage emerging therapies for Chemotherapy-induced Peripheral Neuropathy.

The report also features the SWOT analysis with analyst views for HALNEURON in Chemotherapy-induced Peripheral Neuropathy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HALNEURON Analytical Perspective by DelveInsight

In-depth HALNEURON Market Assessment

This report provides a detailed market assessment of HALNEURON in Chemotherapy-induced Peripheral Neuropathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data for HALNEURON.

HALNEURON Clinical Assessment

The report provides the clinical trials information of HALNEURON for Chemotherapy-induced Peripheral Neuropathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Chemotherapy-induced Peripheral Neuropathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HALNEURON dominance.

Other emerging products for Chemotherapy-induced Peripheral Neuropathy are expected to give tough market competition to HALNEURON and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HALNEURON in Chemotherapy-induced Peripheral Neuropathy.

Our in-depth analysis of the forecasted sales data of HALNEURON will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HALNEURON in Chemotherapy-induced Peripheral Neuropathy.

Key Questions

What is the product type, route of administration and mechanism of action of HALNEURON?

What is the clinical trial status of the study related to HALNEURON in Chemotherapy-induced Peripheral Neuropathy and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HALNEURON development?

What are the key designations that have been granted to HALNEURON for Chemotherapy-induced Peripheral Neuropathy?

What is the forecasted market scenario of HALNEURON for Chemotherapy-induced Peripheral Neuropathy?

What are the forecasted sales of HALNEURON in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Chemotherapy-induced Peripheral Neuropathy and how are they giving competition to HALNEURON for Chemotherapy-induced Peripheral Neuropathy?

Which are the late-stage emerging therapies under development for the treatment of Chemotherapy-induced Peripheral Neuropathy?